Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

PURPOSE: Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yeon Hee, Kim, Tae Yong, Im, Young-Hyuck, Lee, Keun-Seok, Park, In Hae, Sohn, Joohyuk, Lee, Soo-Hyeon, Im, Seock-Ah, Kim, Jee Hyun, Kim, Se Hyun, Lee, Soo Jung, Koh, Su-Jin, Lee, Ki Hyeong, Choi, Yoon Ji, Cho, Eun Kyung, Lee, Suee, Kang, Seok Yun, Seo, Jae Hong, Kim, Sung-Bae, Jung, Kyung Hae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398406/
https://www.ncbi.nlm.nih.gov/pubmed/27488876
http://dx.doi.org/10.4143/crt.2016.191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398406/
https://www.ncbi.nlm.nih.gov/pubmed/27488876
http://dx.doi.org/10.4143/crt.2016.191

Ejemplares similares